特发性肺纤维化药物随机对照试验的入选标准:一项基于登记的研究
本研究评估了III期特发性肺纤维化(IPF)随机对照试验(RCT)的入选标准在临床登记人群中的代表性。在990例IPF患者中,53%符合所有常见RCT入选标准;符合标准者1年用力肺活量(FVC)下降较不符合者更慢(-90 vs -103 mL,p=0.01)。既往IPF RCT的入选标准对临床IPF人群的普遍性有限,且合格与不合格人群的FVC下降存在差异。
要点
- 仅53%的IPF患者符合III期RCT常见入选标准。
- 符合标准者1年FVC下降更慢(-90 vs -103 mL)。
- 添加6分钟步行距离或疾病进展指标会大幅降低合格率。
核心结论
- 既往IPF RCT的入选标准对临床IPF人群的普遍性有限,合格与不合格人群的FVC下降存在差异。
研究设计与样本
- 基于澳大利亚和加拿大前瞻性登记的研究,纳入990例IPF患者,通过文献检索识别>60% IPF RCT使用的常见入选标准并应用,采用联合纵向-生存模型比较FVC下降。
主要发现
- 990例IPF患者中527例(53%)在首次门诊访视时符合所有常见RCT入选标准,包括343例明确IPF和184例放射学可能普通型间质性肺炎(UIP)但无组织学确认(即临时IPF)。
- 符合尼达尼布和吡非尼酮关键RCT入选标准的患者百分比为19-50%。
- 在常见复合标准基础上增加6分钟步行距离(6MWD)≥150 m后,符合标准的患者百分比降至52%(n=516)。
- 在常见复合标准基础上增加不同定义的既往疾病进展指标后,符合标准的患者百分比降至4-18%(n=12-61)。
- 符合常见复合标准者1年FVC下降较不符合者更慢(-90 vs -103 mL,p=0.01);明确IPF通常较临时IPF的1年FVC下降更快。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about generalisability of randomised controlled trials (RCTs) for idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to determine their representativeness in clinical registries, and calculated forced vital capacity (FVC) changes according to eligibility criteria. METHODS: Common eligibility criteria used in >60% of IPF RCTs were identified from a literature search and applied to patients with IPF from prospective Australian and Canadian registries. Additional pre-specified criteria of 6-min walk distance (6MWD) and different measures of preceding disease progression were also evaluated. Joint longitudinal-survival modelling was used to compare FVC decline according to eligibility for individual and composite criteria. RESULTS: Out of 990 patients with IPF, 527 (53%) met all common RCT eligibility criteria at the first clinic visit, including 343 with definite IPF and 184 with radiological probable usual interstitial pneumonia pattern without histological confirmation (i.e. provisional IPF). The percentages of eligible patients for landmark RCTs of nintedanib and pirfenidone were 19-50%. Adding 6MWD ≥150 m and different measures of preceding disease progression to the composite common criteria reduced the percentages of patients meeting eligibility to 52% (n=516) and 4-18% (n=12-61), respectively. Patients meeting the composite common criteria had less-rapid 1-year FVC decline than those who did not (-90 versus -103 mL, p=0.01). Definite IPF generally had more-rapid 1-year FVC decline compared to provisional IPF. CONCLUSIONS: Eligibility criteria of previous IPF RCTs have limited generalisability to clinical IPF populations, with FVC decline differing between eligible and ineligible populations.
引用
- Khor YH, Schulte M, Johannson KA, et al. Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. Eur Respir J. 2023. PMID: 36858445. doi:10.1183/13993003.02163-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。